Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
32
NUWE Quote, Financials, Valuation and Earnings
Last price:
$15.76
Seasonality move
:
-15.57%
Day range:
$14.52 - $25.95
52-week range:
$6.33 - $191.52
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.05x
P/B ratio:
31.00x
Volume:
39.8M
Avg. volume:
2M
1-year change:
-91.71%
Market cap:
$110.9M
Revenue:
$8.7M
EPS (TTM):
-$18.24
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Nuwellis has 2796.56% upside to fair value with a price target of $13.00 per share.
NUWE vs. S&P 500
-
Over the past 5 trading days, Nuwellis has overperformed the S&P 500 by 115.99% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Nuwellis does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Nuwellis has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Nuwellis reported revenues of $1.9M.
Earnings Growth
-
Nuwellis has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Nuwellis reported earnings per share of -$0.69.
Enterprise value:
108.4M
EV / Invested capital:
--
Price / LTM sales:
2.05x
EV / EBIT:
--
EV / Revenue:
12.33x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-11.70x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$5.6M
Return On Assets:
-135.11%
Net Income Margin (TTM):
-112.09%
Return On Equity:
-670.55%
Return On Invested Capital:
-670.55%
Operating Margin:
-160.71%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $8.4M | $8.9M | $8.8M | $1.9M | $1.9M | |
| Gross Profit | $4.7M | $5.1M | $5.6M | $1.2M | $1.1M | |
| Operating Income | -$18.6M | -$16.5M | -$9.3M | -$4.7M | -$3.1M | |
| EBITDA | -$6.4M | -$14.6M | -$4M | -$4.7M | -$3M | |
| Diluted EPS | -$3,021.42 | -$7,053.72 | -$766.08 | -$1,012.62 | -$28.98 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $32.1M | $23.9M | $16.6M | $5.2M | $6.1M | |
| Total Assets | $33.6M | $26.1M | $18.5M | $6.7M | $7M | |
| Current Liabilities | $3.2M | $3.4M | $4.1M | $4.3M | $2.7M | |
| Total Liabilities | $3.2M | $4.4M | $4.8M | $5.8M | $3.4M | |
| Total Equity | $30.4M | $21.7M | $13.7M | $887K | $3.6M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$16.4M | -$14.7M | -$9.3M | -$2.9M | -$2.5M | |
| Cash From Investing | $14.7M | $399K | -$31K | -$29K | -- | |
| Cash From Financing | $9.4M | $4.2M | $10.5M | $500K | -- | |
| Free Cash Flow | -$16.6M | -$14.9M | -$9.3M | -$2.9M | -$2.5M | |
NUWE
Sector
Market Cap
$110.9M
$34.4M
Price % of 52-Week High
8.33%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
-91.71%
-37.36%
Beta (5-Year)
0.281
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$8.42
200-day SMA
Sell
Level
$45.82
Bollinger Bands (100)
Sell
Level
18.54 - 48.98
Chaikin Money Flow
Sell
Level
-44.7M
20-day SMA
Buy
Level
$9.67
Relative Strength Index (RSI14)
Buy
Level
55.83
ADX Line
Buy
Level
29.8
Williams %R
Neutral
Level
-50.9684
50-day SMA
Sell
Level
$23.23
MACD (12, 26)
Sell
Level
-3.48
25-day Aroon Oscillator
Buy
Level
8
On Balance Volume
Neutral
Level
60.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-5.9154)
Sell
CA Score
(Annual)
Level (-2.6833)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (9.7483)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.
Stock Forecast FAQ
In the current month, NUWE has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The NUWE average analyst price target in the past 3 months is $13.00.
-
Where Will Nuwellis Stock Be In 1 Year?
According to analysts, the consensus estimate is that Nuwellis share price will rise to $13.00 per share over the next 12 months.
-
What Do Analysts Say About Nuwellis?
Analysts are divided on their view about Nuwellis share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Nuwellis is a Sell and believe this share price will drop from its current level to $13.00.
-
What Is Nuwellis's Price Target?
The price target for Nuwellis over the next 1-year time period is forecast to be $13.00 according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is NUWE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Nuwellis is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of NUWE?
You can purchase shares of Nuwellis via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Nuwellis shares.
-
What Is The Nuwellis Share Price Today?
Nuwellis was last trading at $15.76 per share. This represents the most recent stock quote for Nuwellis. Yesterday, Nuwellis closed at $15.95 per share.
-
How To Buy Nuwellis Stock Online?
In order to purchase Nuwellis stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
